DATA MATE (@hanqi798) 's Twitter Profile
DATA MATE

@hanqi798

ID: 1551496451548598272

calendar_today25-07-2022 09:16:10

129 Tweet

4 Followers

42 Following

AI University (@therundownu) 's Twitter Profile Photo

99% of people aren't maximizing ChatGPT. We organized ALL of the best resources to make money using ChatGPT into one page. Take advantage of this life-changing opportunity with AI. Free for 48 hrs. Follow, Like, Retweet, Comment ‘ai’ & We’ll DM it to you, for free.

99% of people aren't maximizing ChatGPT.

We organized ALL of the best resources to make money using ChatGPT into one page.

Take advantage of this life-changing opportunity with AI.

Free for 48 hrs.
Follow, Like, Retweet, Comment ‘ai’

& We’ll DM it to you, for free.
Cell (@cellcellpress) 's Twitter Profile Photo

In the latest issue! Single substitution in H3.3G34 alters DNMT3A recruitment to cause progressive neurodegeneration dlvr.it/Sl5fjT

Journal of Experimental Medicine (@jexpmed) 's Twitter Profile Photo

Distinct #fibroblast progenitor subpopulation expedites regenerative mucosal healing by immunomodulation, say Kang Ko, Dana Graves and colleagues Penn Dental Medicine: bit.ly/3Z8lb5D Part of our #Fibrosis Collection 2023: bit.ly/3T4tn4u #KSFibrosis23

Distinct #fibroblast progenitor subpopulation expedites regenerative mucosal healing by immunomodulation, say Kang Ko, Dana Graves and colleagues <a href="/PennDentalMed/">Penn Dental Medicine</a>: bit.ly/3Z8lb5D

Part of our #Fibrosis Collection 2023: bit.ly/3T4tn4u
#KSFibrosis23
NanoTag (@_nanotag_) 's Twitter Profile Photo

A new bioRxiv of our #nanobody binding specifically the post-synaptic protein 95 (#PSD95), is out!. No need for unique treatments; our small FluoTag® works after simple PFA in a one-step IF style, also in tissue and for IHC. Check it out here: biorxiv.org/content/10.110…

A new <a href="/biorxivpreprint/">bioRxiv</a> of our #nanobody binding specifically the post-synaptic protein 95 (#PSD95), is out!. No need for unique treatments; our small FluoTag® works after simple PFA in a one-step IF style, also in tissue and for IHC. Check it out here: biorxiv.org/content/10.110…
RNArtist (@rnartist_app) 's Twitter Profile Photo

Closer look at the animation produced with RNAStudio with a different #RNA. #visualization #java #javafx #kotlin #bioinformatics

Nature Biomedical Engineering (@natbme) 's Twitter Profile Photo

Confining the Zika virus within a self-adjuvanting hydrogel that forms a subcutaneous inflammatory niche stimulates strong immune responses in mice without inducing infection. rdcu.be/c8nV4 [N&V] rdcu.be/c8nWe [Paper]

Confining the Zika virus within a self-adjuvanting hydrogel that forms a subcutaneous inflammatory niche stimulates strong immune responses in mice without inducing infection.

rdcu.be/c8nV4 [N&amp;V]
rdcu.be/c8nWe [Paper]
Cell Biology J-Club (@cell_club) 's Twitter Profile Photo

Single-molecule localization microscopy reveals the ultrastructural constitution of distal appendages in expanded mammalian centrioles nature.com/articles/s4146…

Science Immunology (@sciimmunology) 's Twitter Profile Photo

The compound celastrol from a Chinese medicinal herb called the thunder god vine effectively treats rheumatoid arthritis because it inhibits a relatively unexplored protein complex, finds new research from The University of Osaka #iFReC in mice. scim.ag/25F

The compound celastrol from a Chinese medicinal herb called the thunder god vine effectively treats rheumatoid arthritis because it inhibits a relatively unexplored protein complex, finds new research from <a href="/osaka_univ_e/">The University of Osaka</a> #iFReC in mice. scim.ag/25F
Frontiers - Pharmacology and Toxicology (@frontpharmacol) 's Twitter Profile Photo

New Research: Analyzing the research landscape: Mapping frontiers and hot spots in anti-cancer research using bibliometric analysis and research network pharmacology #pharmacology frontiersin.org/articles/10.33…

背包健客 (@bbjk666) 's Twitter Profile Photo

2024年2月4日——默沙东宣布,其PD-1抑制剂帕博利珠单抗(商品名:可瑞达®)已获得中国国家药品监督管理局批准联合吉西他滨和顺铂用于局部晚期或转移性胆道癌患者的一线治疗。 此次新适应证的获批是基于全球III期临床试验KEYNOTE-966的数据。

2024年2月4日——默沙东宣布,其PD-1抑制剂帕博利珠单抗(商品名:可瑞达®)已获得中国国家药品监督管理局批准联合吉西他滨和顺铂用于局部晚期或转移性胆道癌患者的一线治疗。
此次新适应证的获批是基于全球III期临床试验KEYNOTE-966的数据。
背包健客 (@bbjk666) 's Twitter Profile Photo

2024年2月2日,世界卫生组织国际癌症研究机构(IARC)发布的一篇研究报告显示,2022年全球有2000万新发癌症病例和970癌症死亡,肺癌是全球最常见的新发病例和死亡病例。预计到2050年,全球癌症新发将超过3500万例,与2022年相比,猛增77%。youtu.be/jmh_CsyiFbk?si…

背包健客 (@bbjk666) 's Twitter Profile Photo

2月18日,恒瑞医药宣布其提交的1类新药夫那奇珠单抗注射液(SHR-1314)的新适应症上市许可申请获中国国家药监局受理,本品用于常规治疗疗效欠佳的活动性强直性脊柱炎成人患者。

Frontiers - Immunology (@frontimmunol) 's Twitter Profile Photo

Frontiers in Immunology will be attending ECI Congress 2024! Join us in advancing immunological research and innovation. Don't miss this opportunity to connect with our team 🤝 Send us a message to arrange an in person meeting ⬇️ #ECI2024

Frontiers in Immunology will be attending ECI Congress 2024! Join us in advancing immunological research and innovation. Don't miss this opportunity to connect with our team 🤝

Send us a message to arrange an in person meeting ⬇️

#ECI2024